Full Scope Eyecare Optometrist - Corneal and Contact Management Medicare: Not Enrolled in Medicare Practice Location: 1221 S Ortonville Rd Bldg A, Ortonville, MI 48462 Phone: 248-793-3131 |
News Archive
Pluristem Therapeutics Inc. today reported that data from clinical trials show the Company's placenta-derived cell therapy, PLX-PAD, is safe and improves quality of life as well as other efficacy measurements in patients with Critical Limb Ischemia (CLI), the end-stage of Peripheral Artery Disease (PAD).
Cytokine PharmaSciences, Inc. today announced the completion of a Phase II study of the misoprostol vaginal insert (MVI), a proprietary, controlled-release and retrievable polymer chip containing prostaglandin E(1) (PGE1). Results of the dose-finding study in pregnant women at term gestation confirm the efficacy and safety of this investigational product and suggest that the MVI may reduce time to delivery after induction, support more natural labor, and reduce the rate of cesarean delivery.
Although a deal was struck Tuesday to get a vote on the Senate health bill before Christmas, White House officials said Wednesday that they don't expect a conference bill to pass both houses before President Barack Obama's State of the Union address in late January or early February, Politico reports. Democratic congressional leaders had earlier said they planned to reconcile the differences in the House and Senate measures and send Obama a bill before the speech.
Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).
› Verified 6 days ago